AU‐ARROW (Australia): World‐wide FINGERS network: The first global network of multidomain dementia prevention trials

Ralph N. Martins; Kaarin J. Anstey; Laura D. Baker; Edward Barin; Cintia B. Dias; Belinda M. Brown; Samantha C.  Burnham; Pratishtha Chatterjee; Juliana Chen; Roger Clarnette; Kristine Deang; Tim England; Stephanie J. Fuller; Samantha L. Gardener; Andrew Gleason; Stuart Grieve; Heidi Hillebrandt; Catriona Ireland; Peter Kenny; Mila Kivipelto; Rowena Mobbs; Sharon L. Naismith; Ruth Peters; Stephanie R. Rainey-Smith; Rema Raman; Greg Savage; Hamid Sohrabi; Tejal M. Shah; Genevieve Z. Steiner; Kevin Taddei; Belinda Thompson; Victor L. L. Villemagne; Paul A. Yates

doi:10.1002/alz.046955

AU‐ARROW (Australia): World‐wide FINGERS network: The first global network of multidomain dementia prevention trials

Ralph N. Martins, Kaarin J. Anstey, Laura D. Baker, Edward Barin, Cintia B. Dias, Belinda M. Brown, Samantha C. Burnham, Pratishtha Chatterjee, Juliana Chen, Roger Clarnette, Kristine Deang, Tim England, Stephanie J. Fuller, Samantha L. Gardener, Andrew Gleason, Stuart Grieve, Heidi Hillebrandt, Catriona Ireland, Peter Kenny, Mila KivipeltoRowena Mobbs, Sharon L. Naismith, Ruth Peters, Stephanie R. Rainey-Smith, Rema Raman, Greg Savage, Hamid Sohrabi, Tejal M. Shah, Genevieve Z. Steiner, Kevin Taddei, Belinda Thompson, Victor L. L. Villemagne, Paul A. Yates

Research output: Contribution to journal › Meeting abstract › peer-review

Abstract

Background: The highly encouraging findings from the Finnish Geriatric Intervention Study (known as FINGER) led to the global initiative for dementia risk reduction known as world‐wide FINGERS (WW FINGERS). As part of the collaboration, our Australian AU‐ARROW trial will follow the general protocol of the FINGER trial, and will also be aligned with the U.S. arm of the study, US‐POINTER, though will have minor cultural and dietary modifications to determine the validity of the intervention in an Australian setting.

Method: AU‐ARROW is a randomised, single‐blind 2‐year clinical trial that will recruit 600 participants aged 60‐79 satisfying specific inclusion/exclusion criteria, including normal cognition and one or more cardiovascular risk factors that place them at greater risk of cognitive decline. Participants will be distributed across two sites (a) Macquarie University Health Clinics, Sydney, NSW and (b) Sarich Neuroscience Research Institute, Edith Cowan University, Perth, WA, and will be randomised equally into either the innovative multi‐modal intervention group or the study control group, who will receive general lifestyle advice and annual health check‐ups, without treatment. Multi‐modal intervention consists of aerobic exercise, resistance training and stretching; dietary advice with monitoring to encourage adherence to the MIND diet; cognitive training sessions via the Brain HQ computerised online training system; and medical monitoring and regular health education sessions. Heart rate trackers, diet and exercise log books, and the monitoring of Brain HQ sessions will all help with adherence. Primary outcome measure is improvement in global cognitive score, measured using neurocognitive tests identical to those in the US‐POINTER protocol. Additional neurocognitive tests, physical function improvements, detailed diet monitoring and sleep monitoring will provide added data. The unique extra value of AU‐ARROW trial consists of the testing for Alzheimer’s disease (AD) blood biomarkers in all participants; as well as the AD Aβ amyloid‐specific ligand‐PET imaging, brain MRI and retinal biomarker tests that half of the participants will undergo. These tests will provide comprehensive data which have the ultimate purpose of increasing knowledge of the preclinical stages of AD, and help not only to develop preclinical AD diagnostic tests but also efficacy of AU‐ARROW’s intervention.

Original language	English
Article number	e046955
Pages (from-to)	1-2
Number of pages	2
Journal	Alzheimer's and Dementia
Volume	16
Issue number	S10
DOIs	https://doi.org/10.1002/alz.046955
Publication status	Published - Dec 2020
Event	Alzheimer's Association International Conference 2020 - Virtual conference Duration: 27 Jul 2020 → 31 Jul 2020

Access to Document

10.1002/alz.046955

Cite this

Martins, R. N., Anstey, K. J., Baker, L. D., Barin, E., Dias, C. B., Brown, B. M., Burnham, S. C., Chatterjee, P., Chen, J., Clarnette, R., Deang, K., England, T., Fuller, S. J., Gardener, S. L., Gleason, A., Grieve, S., Hillebrandt, H., Ireland, C., Kenny, P., ... Yates, P. A. (2020). AU‐ARROW (Australia): World‐wide FINGERS network: The first global network of multidomain dementia prevention trials. Alzheimer's and Dementia, 16(S10), 1-2. [e046955]. https://doi.org/10.1002/alz.046955

@article{ed448243b1fd4aecb7e71408e1d3e942,

title = "AU‐ARROW (Australia): World‐wide FINGERS network: The first global network of multidomain dementia prevention trials",

abstract = "Background: The highly encouraging findings from the Finnish Geriatric Intervention Study (known as FINGER) led to the global initiative for dementia risk reduction known as world‐wide FINGERS (WW FINGERS). As part of the collaboration, our Australian AU‐ARROW trial will follow the general protocol of the FINGER trial, and will also be aligned with the U.S. arm of the study, US‐POINTER, though will have minor cultural and dietary modifications to determine the validity of the intervention in an Australian setting. Method: AU‐ARROW is a randomised, single‐blind 2‐year clinical trial that will recruit 600 participants aged 60‐79 satisfying specific inclusion/exclusion criteria, including normal cognition and one or more cardiovascular risk factors that place them at greater risk of cognitive decline. Participants will be distributed across two sites (a) Macquarie University Health Clinics, Sydney, NSW and (b) Sarich Neuroscience Research Institute, Edith Cowan University, Perth, WA, and will be randomised equally into either the innovative multi‐modal intervention group or the study control group, who will receive general lifestyle advice and annual health check‐ups, without treatment. Multi‐modal intervention consists of aerobic exercise, resistance training and stretching; dietary advice with monitoring to encourage adherence to the MIND diet; cognitive training sessions via the Brain HQ computerised online training system; and medical monitoring and regular health education sessions. Heart rate trackers, diet and exercise log books, and the monitoring of Brain HQ sessions will all help with adherence. Primary outcome measure is improvement in global cognitive score, measured using neurocognitive tests identical to those in the US‐POINTER protocol. Additional neurocognitive tests, physical function improvements, detailed diet monitoring and sleep monitoring will provide added data. The unique extra value of AU‐ARROW trial consists of the testing for Alzheimer{\textquoteright}s disease (AD) blood biomarkers in all participants; as well as the AD Aβ amyloid‐specific ligand‐PET imaging, brain MRI and retinal biomarker tests that half of the participants will undergo. These tests will provide comprehensive data which have the ultimate purpose of increasing knowledge of the preclinical stages of AD, and help not only to develop preclinical AD diagnostic tests but also efficacy of AU‐ARROW{\textquoteright}s intervention.",

author = "Martins, {Ralph N.} and Anstey, {Kaarin J.} and Baker, {Laura D.} and Edward Barin and Dias, {Cintia B.} and Brown, {Belinda M.} and Burnham, {Samantha C.} and Pratishtha Chatterjee and Juliana Chen and Roger Clarnette and Kristine Deang and Tim England and Fuller, {Stephanie J.} and Gardener, {Samantha L.} and Andrew Gleason and Stuart Grieve and Heidi Hillebrandt and Catriona Ireland and Peter Kenny and Mila Kivipelto and Rowena Mobbs and Naismith, {Sharon L.} and Ruth Peters and Rainey-Smith, {Stephanie R.} and Rema Raman and Greg Savage and Hamid Sohrabi and Shah, {Tejal M.} and Steiner, {Genevieve Z.} and Kevin Taddei and Belinda Thompson and Villemagne, {Victor L. L.} and Yates, {Paul A.}",

year = "2020",

month = dec,

doi = "10.1002/alz.046955",

language = "English",

volume = "16",

pages = "1--2",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Wiley-Blackwell, Wiley",

number = "S10",

note = "Alzheimer's Association International Conference 2020 ; Conference date: 27-07-2020 Through 31-07-2020",

}

Martins, RN, Anstey, KJ, Baker, LD, Barin, E, Dias, CB, Brown, BM, Burnham, SC, Chatterjee, P, Chen, J, Clarnette, R, Deang, K, England, T, Fuller, SJ, Gardener, SL, Gleason, A, Grieve, S, Hillebrandt, H, Ireland, C, Kenny, P, Kivipelto, M, Mobbs, R, Naismith, SL, Peters, R, Rainey-Smith, SR, Raman, R, Savage, G , Sohrabi, H , Shah, TM, Steiner, GZ, Taddei, K, Thompson, B, Villemagne, VLL & Yates, PA 2020, 'AU‐ARROW (Australia): World‐wide FINGERS network: The first global network of multidomain dementia prevention trials', Alzheimer's and Dementia, vol. 16, no. S10, e046955, pp. 1-2. https://doi.org/10.1002/alz.046955

TY - JOUR

T1 - AU‐ARROW (Australia)

T2 - Alzheimer's Association International Conference 2020

AU - Martins, Ralph N.

AU - Anstey, Kaarin J.

AU - Baker, Laura D.

AU - Barin, Edward

AU - Dias, Cintia B.

AU - Brown, Belinda M.

AU - Burnham, Samantha C.

AU - Chatterjee, Pratishtha

AU - Chen, Juliana

AU - Clarnette, Roger

AU - Deang, Kristine

AU - England, Tim

AU - Fuller, Stephanie J.

AU - Gardener, Samantha L.

AU - Gleason, Andrew

AU - Grieve, Stuart

AU - Hillebrandt, Heidi

AU - Ireland, Catriona

AU - Kenny, Peter

AU - Kivipelto, Mila

AU - Mobbs, Rowena

AU - Naismith, Sharon L.

AU - Peters, Ruth

AU - Rainey-Smith, Stephanie R.

AU - Raman, Rema

AU - Savage, Greg

AU - Sohrabi, Hamid

AU - Shah, Tejal M.

AU - Steiner, Genevieve Z.

AU - Taddei, Kevin

AU - Thompson, Belinda

AU - Villemagne, Victor L. L.

AU - Yates, Paul A.

PY - 2020/12

Y1 - 2020/12

N2 - Background: The highly encouraging findings from the Finnish Geriatric Intervention Study (known as FINGER) led to the global initiative for dementia risk reduction known as world‐wide FINGERS (WW FINGERS). As part of the collaboration, our Australian AU‐ARROW trial will follow the general protocol of the FINGER trial, and will also be aligned with the U.S. arm of the study, US‐POINTER, though will have minor cultural and dietary modifications to determine the validity of the intervention in an Australian setting. Method: AU‐ARROW is a randomised, single‐blind 2‐year clinical trial that will recruit 600 participants aged 60‐79 satisfying specific inclusion/exclusion criteria, including normal cognition and one or more cardiovascular risk factors that place them at greater risk of cognitive decline. Participants will be distributed across two sites (a) Macquarie University Health Clinics, Sydney, NSW and (b) Sarich Neuroscience Research Institute, Edith Cowan University, Perth, WA, and will be randomised equally into either the innovative multi‐modal intervention group or the study control group, who will receive general lifestyle advice and annual health check‐ups, without treatment. Multi‐modal intervention consists of aerobic exercise, resistance training and stretching; dietary advice with monitoring to encourage adherence to the MIND diet; cognitive training sessions via the Brain HQ computerised online training system; and medical monitoring and regular health education sessions. Heart rate trackers, diet and exercise log books, and the monitoring of Brain HQ sessions will all help with adherence. Primary outcome measure is improvement in global cognitive score, measured using neurocognitive tests identical to those in the US‐POINTER protocol. Additional neurocognitive tests, physical function improvements, detailed diet monitoring and sleep monitoring will provide added data. The unique extra value of AU‐ARROW trial consists of the testing for Alzheimer’s disease (AD) blood biomarkers in all participants; as well as the AD Aβ amyloid‐specific ligand‐PET imaging, brain MRI and retinal biomarker tests that half of the participants will undergo. These tests will provide comprehensive data which have the ultimate purpose of increasing knowledge of the preclinical stages of AD, and help not only to develop preclinical AD diagnostic tests but also efficacy of AU‐ARROW’s intervention.

AB - Background: The highly encouraging findings from the Finnish Geriatric Intervention Study (known as FINGER) led to the global initiative for dementia risk reduction known as world‐wide FINGERS (WW FINGERS). As part of the collaboration, our Australian AU‐ARROW trial will follow the general protocol of the FINGER trial, and will also be aligned with the U.S. arm of the study, US‐POINTER, though will have minor cultural and dietary modifications to determine the validity of the intervention in an Australian setting. Method: AU‐ARROW is a randomised, single‐blind 2‐year clinical trial that will recruit 600 participants aged 60‐79 satisfying specific inclusion/exclusion criteria, including normal cognition and one or more cardiovascular risk factors that place them at greater risk of cognitive decline. Participants will be distributed across two sites (a) Macquarie University Health Clinics, Sydney, NSW and (b) Sarich Neuroscience Research Institute, Edith Cowan University, Perth, WA, and will be randomised equally into either the innovative multi‐modal intervention group or the study control group, who will receive general lifestyle advice and annual health check‐ups, without treatment. Multi‐modal intervention consists of aerobic exercise, resistance training and stretching; dietary advice with monitoring to encourage adherence to the MIND diet; cognitive training sessions via the Brain HQ computerised online training system; and medical monitoring and regular health education sessions. Heart rate trackers, diet and exercise log books, and the monitoring of Brain HQ sessions will all help with adherence. Primary outcome measure is improvement in global cognitive score, measured using neurocognitive tests identical to those in the US‐POINTER protocol. Additional neurocognitive tests, physical function improvements, detailed diet monitoring and sleep monitoring will provide added data. The unique extra value of AU‐ARROW trial consists of the testing for Alzheimer’s disease (AD) blood biomarkers in all participants; as well as the AD Aβ amyloid‐specific ligand‐PET imaging, brain MRI and retinal biomarker tests that half of the participants will undergo. These tests will provide comprehensive data which have the ultimate purpose of increasing knowledge of the preclinical stages of AD, and help not only to develop preclinical AD diagnostic tests but also efficacy of AU‐ARROW’s intervention.

U2 - 10.1002/alz.046955

DO - 10.1002/alz.046955

M3 - Meeting abstract

VL - 16

SP - 1

EP - 2

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - S10

M1 - e046955

Y2 - 27 July 2020 through 31 July 2020

ER -

AU‐ARROW (Australia): World‐wide FINGERS network: The first global network of multidomain dementia prevention trials

Abstract

Access to Document

Fingerprint

Cite this